Non-Alcoholic Steatohepatitis (NASH) Biomarkers Market 2021-2024: Industry Size & Share, Segmentation, Growth Opportunities, Regional Analysis

Non-alcoholic steatohepatitis (NASH) is liver disease which is categorized under the spectrum of non-alcoholic fatty liver disease (NAFLD). NASH is an advanced form of NAFLD where the liver inflammation occurs owing to fat deposition in liver. The fat accumulation may be induced by genetic abnormalities, metabolic dysfunction, drug induced damages, etc. Untreated and advanced NASH is one of the major reason for liver cirrhosis and sever liver damage such as liver failure. Presently three distinct method are used for diagnosis and monitoring of NASH, those are biopsy derived histopathology, imaging tools like transient elastography (TE), magnetic resonance imaging (MRI), etc., and in vitro diagnostic using biomarkers. As per the World Gastroenterology Organization It is estimated that around 20% to 30% of world population is affected with NAFLD.

Get Free Sample PDF for Professional Insights: https://www.researchmoz.us/enquiry.php?type=S&repid=964528

Biomarkers Market, by Marker Type
Serum Biomarkers
Hepatic Fibrosis Biomarkers
Apoptosis Biomarkers
Oxidative Stress Biomarkers
Others
Global Non-alcoholic Steatohepatitis (NASH)

Biomarkers Market, by End-User
Contract Research Organization(CRO) & Pharmaceutical Industry
Academic Research Institutes
Hospitals
Diagnostic Laboratories

Select License Type
Single User License $5795
Table of Content
Check Discount
Research Assistance

Enquiry for Discount or to Get Customized Report: https://www.researchmoz.us/enquiry.php?type=S&repid=964528

Increasing prevalence of NASH associated conditions like obesity and diabetes are expected to drive the growth of NASH biomarkers market. According to Deutsche Bank around 45 million people are anticipated to be affected by NASH in the U.S. and EU5 countries by 2025. Also there are many industry players investing on development of NASH therapeutic drugs, and most of them are in phase II or III of clinical trials. Their requirement of non-invasive diagnostic tools for monitoring their drug effectiveness is expected to drive the growth for NASH biomarkers market over the forecasted period. Biomarkers based NASH diagnostic tests are proposed to be at lower cost and non-invasive which is expected to make them a preferred tool for NASH diagnosis over invasive liver biopsy and costly imaging techniques. Ongoing research in discovery and development of novel NASH biomarkers is expected to drive the growth of NASH biomarkers market. However presently available NASH biomarkers are less accurate and have little efficacy which makes their usage limited. Also their results are overlapping with other metabolic disorders which is anticipated to restrain the growth of NASH biomarkers market.

About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfil all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organisations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.



This release was published on openPR.